Why Is Prescription Digital Medicine-Focused Akili Stock Trading Over 100% On Monday?
Portfolio Pulse from Vandana Singh
Akili Inc (NASDAQ:AKLI) shares surged over 100% after announcing its partner Shionogi submitted the digital therapeutic SDT-001 for marketing approval in Japan. SDT-001, a localized version of Akili's EndeavorRx, aims to improve attention in pediatric ADHD patients. The submission follows a successful Phase 3 trial demonstrating significant improvements in ADHD symptoms with no safety concerns.
February 26, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akili Inc's stock soared over 100% following the announcement of its Japanese partner Shionogi submitting SDT-001 for marketing approval in Japan, indicating strong investor optimism.
The significant stock price increase is directly tied to the positive news of SDT-001's submission for marketing approval in Japan, based on successful Phase 3 trial results. This development is seen as a major step forward for Akili, potentially opening up a new market for its digital therapeutic product. The positive trial results and the lack of safety concerns add to investor confidence, suggesting a strong short-term bullish sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100